Satavaptan

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Satavaptan
Satavaptan structure.svg
Clinical data
ATC code
  • none
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
ECHA InfoCard 100.211.853
Chemical and physical data
Formula C33H45N3O8S
Molar mass 643.789 g/mol
3D model (Jmol)
 NYesY (what is this?)  (verify)

Satavaptan (INN; codenamed SR121463, planned tradename Aquilda) is a vasopressin-2 receptor antagonist[1] undergoing research for the treatment of hyponatremia. It is also being studied for the treatment of ascites.[2]

It was developed by Sanofi-Aventis. As of 2008, it is under regulatory review in the European Union.

References[edit]

  1. ^ Soupart A, Gross P, Legros JJ, et al. (November 2006). "Successful long-term treatment of hyponatremia in syndrome of inappropriate antidiuretic hormone secretion with satavaptan (SR121463B), an orally active nonpeptide vasopressin V2-receptor antagonist". Clin J Am Soc Nephrol. 1 (6): 1154–1160. doi:10.2215/CJN.00160106. PMID 17699341. 
  2. ^ Ginès P; Wong F; Watson H; Milutinovic S; Ruiz Del Arbol L; Olteanu D (February 2008). "Effects of satavaptan, a selective vasopressin V(2) receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: A randomized trial". Hepatology. 48 (1): 204–213. doi:10.1002/hep.22293. PMID 18508290.